A Phase 2 interventional study of Collagenase Clostridium Histolyticum and Placebo in Adhesive Capsulitis and Frozen Shoulder, sponsored by Endo Pharmaceuticals. Completed at 46 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-05.
Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Bursitis with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Bursitis · United States.
Among the 45 studies in Bursitis with a site in United States, this one is the 4th largest by enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2013, is one of 6 in phase 2, and was the 20th registered.
383 studies on the registry are indexed under Bursitis; 111 are open to participants now.
Browse Bursitis studies →4 of the 45 studies in Bursitis with a site in United States are open now. Recruiting first, the newest first:
University of Maryland, Baltimore · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 40+ · Women only
Massachusetts General Hospital · Sites in United States
Ages 18+ · Healthy volunteers
University Hospitals Cleveland Medical Center · Sites in United States
Ages 18–89
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 64 Bursitis studies recruiting now, 17 (27%) set no upper age limit and 40 (63%) stop at 75 or younger; none take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 5 · Phase 4 8
First in 1997; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 322 is above the median of 44 across 346 interventional studies indexed under Bursitis.
Median enrollment 40 across the 41 interventional studies, 38 across the 4 observational. Of the 33 that completed or were terminated, 11 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 45 have an industry lead sponsor. The 10 most frequent:
This study is registered under Endo Pharmaceuticals, one of the names counted as Keenova Therapeutics plc. Under that name alone:
Endo Pharmaceuticals is the lead sponsor of 99 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.
Keenova Therapeutics plc has 4 studies filed under Bursitis — fewer than ten, so there is no comparison to draw.
4 of the studies in Bursitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07278323University of California, San FranciscoFrozen Shoulder and Hormone Replacement Therapy | 2026-12 |
| NCT02283996Massachusetts General HospitalAdhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment | 2026-12 |
| NCT07227662University of Maryland, BaltimoreFeasibility, Usability and Preliminary Efficacy of Home-based FES Fro Adhesive Capsulitis | 2026-12-01 |
| NCT07497737University Hospitals Cleveland Medical CenterOMT for Adhesive Capsulitis | 2027-04-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 45 studies in Bursitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objectives of this study are to assess the safety, effectiveness, and immunogenicity of AA4500 in the treatment of adhesive capsulitis.
Study is a Phase 2b, double-blind, placebo-controlled study of the safety and efficacy of AA4500 for the treatment of adhesive capsulitis of the shoulder. To be eligible for treatment, a subject must have unilateral idiopathic adhesive capsulitis of the shoulder with restricted range of motion in the affected shoulder for at least 3 months but not more than 12 months. Subjects will be screened for study eligibility within 28 days before injection of study drug.
Approximately 300 adult women and men are to be enrolled in this study. Following screening and determination of study eligibility, subjects will be randomized 3:1 to receive 0.58 mg of AA4500 or placebo. Subjects will receive up to 3 injections of study drug. Each injection will be separated by a minimum of 21 days. Subjects will also be instructed in home shoulder exercises after the first injection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Restricted active range of motion (AROM) in the affected shoulder defined as: a deficit of at least 60 degrees in total AROM in the affected shoulder as compared with the total AROM in the contralateral shoulder and a deficit of at least 30 degrees in AROM in at least one of the following planes as compared with the contralateral shoulder:
Exclusion Criteria:
Has received treatment for adhesive capsulitis or is planning to receive treatment for adhesive capsulitis at any time during the study including but not limited to:
Has any of the following conditions, as determined by investigator to be potentially confounding to the evaluation of safety and efficacy:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Up to 3 injections of .58 mg/1 mL of collagenase clostridium histolyticum (CCH), minimum of 21 days apart and home shoulder exercise.
Biological: Collagenase Clostridium Histolyticum
Up to 3 1-mL injections of placebo, minimum of 21 days apart and home shoulder exercise.
Other: Placebo
Treatment of Adhesive Capsulitis
Also known as: AA4500, Xiaflex, Xiapex
Placebo injection
Change From Baseline to Day 95 in Active Forward Flexion
Active range of motion (AROM) measurement using a goniometer to assess forward flexion in the affected shoulder
Time frame: Baseline, day 95
Change From Baseline to Day 95 in Adapted American Shoulder and Elbow Surgeons (ASES) Function Subscale
Function subscale score ranging from 0-50, with 0 being most dysfunctional, derived from participant assessment of ability to do 10 activities with affected shoulder/arm where 0=unable to do to, 1=very difficult to do, 2=somewhat difficult, and 3=not difficult, and calculated as (cumulative total score for the 10 activity items) × (5/3); adapted from ASES Standardized Shoulder Assessment Form, Patient Self-Evaluation (United States adapted version).
Time frame: Baseline, day 95
Change From Baseline to Day 95 in Pain With Movement Using 11-point Numeric Rating Scale (NRS)
Participant assessment of pain in response to "How bad is the pain upon movement of your affected shoulder at its worst in the last 24 hours?" using an 11-point NRS where 0=no pain at all and 10=pain as bad as it can be.
Time frame: Baseline, day 95
Change From Baseline to Day 95 in Active Abduction
AROM measurement using a goniometer to assess abduction in the affected shoulder
Time frame: Baseline, day 95
Change From Baseline to Day 95 in Passive Forward Flexion
Passive range of motion (PROM) measurement using a goniometer to assess forward flexion in the affected shoulder
Time frame: Baseline, day 95
Change From Baseline to Day 95 in Passive Abduction
PROM measurement using a goniometer to assess abduction in the affected shoulder
Time frame: Baseline, day 95
Change From Baseline to Day 95 in Active Internal Rotation
AROM measurement using a goniometer to assess internal rotation in the affected shoulder
Time frame: Baseline, day 95
Change From Baseline to Day 95 in Active External Rotation
AROM measurement using a goniometer to assess external rotation in the affected shoulder
Time frame: Baseline, day 95
Change From Baseline to Day 95 in Passive Internal Rotation
PROM measurement using a goniometer to assess internal rotation in the affected shoulder
Time frame: Baseline, day 95
Change From Baseline to Day 95 in Passive External Rotation
PROM measurement using a goniometer to assess external rotation in the affected shoulder
Time frame: Baseline, day 95
Change From Baseline to Day 95 in Adapted ASES Pain Subscale
Pain subscale score ranging from 0-50, with 0 being greatest pain, derived from participant overall assessment of pain in response to "How bad is the pain in your affected shoulder today?" using an 11-point NRS where 0=no pain at all and 10=pain as bad as it can be and calculated as (10 - NRS score) x 5; adapted from ASES Standardized Shoulder Assessment Form, Patient Self-Evaluation
Time frame: Baseline, day 95
Subject Satisfaction With Treatment at Day 95
Participant assessment of satisfaction with treatment rated as very satisfied, quite satisfied, neither satisfied nor dissatisfied, quite dissatisfied, or very dissatisfied.
Time frame: Day 95
Investigator Assessment of Improvement With Treatment at Day 95
Investigator assessment of degree of improvement in severity of the participant's treated shoulder compared with screening rated as very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse.
Time frame: Day 95
| Milestone | AA4500 | Placebo |
|---|---|---|
| Started | 237 | 85 |
| Completed | 219 | 80 |
| Not completed | 18 | 5 |
| Withdrew: Withdrawal by subject | 10 | 2 |
| Withdrew: Lost to follow-up | 5 | 1 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Other/unknown | 0 | 1 |
Active range of motion (AROM) measurement using a goniometer to assess forward flexion in the affected shoulder
| degrees | AA4500 | Placebo |
|---|---|---|
| Change From Baseline to Day 95 in Active Forward Flexion | 41.0 ± 28.89 | 35.9 ± 23.36 |
Function subscale score ranging from 0-50, with 0 being most dysfunctional, derived from participant assessment of ability to do 10 activities with affected shoulder/arm where 0=unable to do to, 1=very difficult to do, 2=somewhat difficult, and 3=not difficult, and calculated as (cumulative total score for the 10 activity items) × (5/3); adapted from ASES Standardized Shoulder Assessment Form, Patient Self-Evaluation (United States adapted version).
| units on a scale | AA4500 | Placebo |
|---|---|---|
| Change From Baseline to Day 95 in Adapted American Shoulder and Elbow Surgeons (ASES) Function Subscale | 17.0 ± 11.65 | 14.8 ± 11.14 |
Participant assessment of pain in response to "How bad is the pain upon movement of your affected shoulder at its worst in the last 24 hours?" using an 11-point NRS where 0=no pain at all and 10=pain as bad as it can be.
| units on a scale | AA4500 | Placebo |
|---|---|---|
| Change From Baseline to Day 95 in Pain With Movement Using 11-point Numeric Rating Scale (NRS) | -4.4 ± 2.83 | -3.9 ± 2.93 |
AROM measurement using a goniometer to assess abduction in the affected shoulder
| degrees | AA4500 | Placebo |
|---|---|---|
| Change From Baseline to Day 95 in Active Abduction | 49.0 ± 33.10 | 43.8 ± 30.71 |
Passive range of motion (PROM) measurement using a goniometer to assess forward flexion in the affected shoulder
| degrees | AA4500 | Placebo |
|---|---|---|
| Change From Baseline to Day 95 in Passive Forward Flexion | 39.3 ± 29.47 | 34.1 ± 22.37 |
PROM measurement using a goniometer to assess abduction in the affected shoulder
| degrees | AA4500 | Placebo |
|---|---|---|
| Change From Baseline to Day 95 in Passive Abduction | 45.4 ± 33.69 | 42.8 ± 32.12 |
AROM measurement using a goniometer to assess internal rotation in the affected shoulder
| degrees | AA4500 | Placebo |
|---|---|---|
| Change From Baseline to Day 95 in Active Internal Rotation | 23.1 ± 25.21 | 20.9 ± 23.58 |
AROM measurement using a goniometer to assess external rotation in the affected shoulder
| degrees | AA4500 | Placebo |
|---|---|---|
| Change From Baseline to Day 95 in Active External Rotation | 28.6 ± 21.30 | 26.1 ± 22.67 |
PROM measurement using a goniometer to assess internal rotation in the affected shoulder
| degrees | AA4500 | Placebo |
|---|---|---|
| Change From Baseline to Day 95 in Passive Internal Rotation | 24.1 ± 23.77 | 20.3 ± 23.61 |
PROM measurement using a goniometer to assess external rotation in the affected shoulder
| degrees | AA4500 | Placebo |
|---|---|---|
| Change From Baseline to Day 95 in Passive External Rotation | 24.8 ± 22.31 | 24.4 ± 26.16 |
Pain subscale score ranging from 0-50, with 0 being greatest pain, derived from participant overall assessment of pain in response to "How bad is the pain in your affected shoulder today?" using an 11-point NRS where 0=no pain at all and 10=pain as bad as it can be and calculated as (10 - NRS score) x 5; adapted from ASES Standardized Shoulder Assessment Form, Patient Self-Evaluation
| units on a scale | AA4500 | Placebo |
|---|---|---|
| Change From Baseline to Day 95 in Adapted ASES Pain Subscale | 15.9 ± 13.46 | 13.5 ± 13.45 |
Participant assessment of satisfaction with treatment rated as very satisfied, quite satisfied, neither satisfied nor dissatisfied, quite dissatisfied, or very dissatisfied.
| participants | AA4500 | Placebo |
|---|---|---|
| Very satisfied | 142 | 43 |
| Quite satisfied | 38 | 22 |
| Neither satisfied nor dissatisfied | 32 | 8 |
| Quite dissatisfied | 10 | 2 |
| Very dissatisfied | 7 | 6 |
Investigator assessment of degree of improvement in severity of the participant's treated shoulder compared with screening rated as very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse.
| participants | AA4500 | Placebo |
|---|---|---|
| Very much improved | 94 | 27 |
| Much improved | 73 | 31 |
| Minimally improved | 41 | 16 |
| No change | 13 | 8 |
| Minimally worse | 6 | 0 |
| Much worse | 1 | 0 |
| Very much worse | 1 | 0 |
Collected over 130 days (up to 28 day screening period and 95±7 day study period). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AA4500 | — | 4/237 (1.7%) | 188/237 (79.3%) |
| Placebo | — | 1/84 (1.2%) | 37/84 (44%) |
| Event | AA4500 | Placebo |
|---|---|---|
| Gastric ulcerGastrointestinal disorders | 0/237 | 1/84 |
| Atrial fibrilationCardiac disorders | 1/237 | 0/84 |
| GlioblastomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/237 | 0/84 |
| OverdoseInjury, poisoning and procedural complications | 1/237 | 0/84 |
| Post procedural bile leakInjury, poisoning and procedural complications | 1/237 | 0/84 |
| Procedural painInjury, poisoning and procedural complications | 1/237 | 0/84 |
| Event | AA4500 | Placebo |
|---|---|---|
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 90/237 | 18/84 |
| ContusionInjury, poisoning and procedural complications | 71/237 | 2/84 |
| Injection site bruisingGeneral disorders | 52/237 | 10/84 |
| Injection site painGeneral disorders | 50/237 | 11/84 |
| EcchymosisSkin and subcutaneous tissue disorders | 47/237 | 3/84 |
| Localised oedemaGeneral disorders | 20/237 | 1/84 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 13/237 | 4/84 |
| PruritusSkin and subcutaneous tissue disorders | 12/237 | 0/84 |
All participants who received at least 1 administration of study drug (1 participant excluded)
| Age, Continuous(years) | AA4500 | Placebo | Total |
|---|---|---|---|
| Median | 53.0 (29 to 75) | 51.0 (22 to 70) | 52.0 (22 to 75) |
| Age, Customized(Participants) | AA4500 | Placebo | Total |
|---|---|---|---|
| <45 | 30 | 14 | 44 |
| 45-54 | 114 | 44 | 158 |
| 55-64 | 75 | 23 | 98 |
| 65-74 | 17 | 3 | 20 |
| ≥75 | 1 | 0 | 1 |
| Sex: Female, Male(Participants) | AA4500 | Placebo | Total |
|---|---|---|---|
| Female | 162 | 60 | 222 |
| Male | 75 | 24 | 99 |
| Ethnicity (NIH/OMB)(Participants) | AA4500 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 17 | 4 | 21 |
| Not Hispanic or Latino | 220 | 80 | 300 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | AA4500 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 6 | 4 | 10 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 2 |
| Black or African American | 22 | 7 | 29 |
| White | 205 | 72 | 277 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 1 | 0 | 1 |
The record gives a start of Nov 2013, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in May 2017, 2 years 5 months after primary completion. A results delay was requested in Mar 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Microbial Collagenase